Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Reflux Disease (GERD)
Conditions
Gastroesophageal Reflux Disease (GERD)
Trial Timeline
Dec 1, 2007 → Feb 1, 2012
NCT ID
NCT00747526About Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg
Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg is a phase 1 stage product being developed by Eisai for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00747526. Target conditions include Gastroesophageal Reflux Disease (GERD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00747526 | Phase 1 | Completed |
Competing Products
20 competing products in Gastroesophageal Reflux Disease (GERD)